WO2003018606A3 - Casein derived peptides and uses thereof in therapy - Google Patents

Casein derived peptides and uses thereof in therapy Download PDF

Info

Publication number
WO2003018606A3
WO2003018606A3 PCT/IL2002/000720 IL0200720W WO03018606A3 WO 2003018606 A3 WO2003018606 A3 WO 2003018606A3 IL 0200720 W IL0200720 W IL 0200720W WO 03018606 A3 WO03018606 A3 WO 03018606A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
therapy
casein
derived peptides
derived
Prior art date
Application number
PCT/IL2002/000720
Other languages
French (fr)
Other versions
WO2003018606A9 (en
WO2003018606A2 (en
Inventor
Zvi Sidelman
Original Assignee
Chay 13 Medical Res Group N V
Zvi Sidelman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/942,121 external-priority patent/US20020147144A1/en
Priority to KR10-2004-7002884A priority Critical patent/KR20040078639A/en
Priority to JP2003523265A priority patent/JP2005511499A/en
Priority to IL16054802A priority patent/IL160548A0/en
Priority to CA002458924A priority patent/CA2458924A1/en
Priority to BRPI0212625-7A priority patent/BR0212625A/en
Priority to MXPA04001890A priority patent/MXPA04001890A/en
Priority to HU0500995A priority patent/HUP0500995A3/en
Priority to EP02758768A priority patent/EP1556074A4/en
Priority to AU2002324323A priority patent/AU2002324323A2/en
Priority to EA200400376A priority patent/EA007814B1/en
Application filed by Chay 13 Medical Res Group N V, Zvi Sidelman filed Critical Chay 13 Medical Res Group N V
Publication of WO2003018606A2 publication Critical patent/WO2003018606A2/en
Priority to NO20040880A priority patent/NO20040880L/en
Priority to US10/788,400 priority patent/US7666996B2/en
Publication of WO2003018606A9 publication Critical patent/WO2003018606A9/en
Publication of WO2003018606A3 publication Critical patent/WO2003018606A3/en
Priority to US11/982,369 priority patent/US20090192081A1/en
Priority to US12/844,834 priority patent/US20100317601A1/en
Priority to US13/603,428 priority patent/US8735348B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the S1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases.
PCT/IL2002/000720 2000-03-01 2002-08-29 Casein derived peptides and uses thereof in therapy WO2003018606A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2003523265A JP2005511499A (en) 2001-08-30 2002-08-29 Casein-derived peptide and its medical use
EA200400376A EA007814B1 (en) 2000-03-01 2002-08-29 Casein derived peptides and uses thereof in therapy
AU2002324323A AU2002324323A2 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy
CA002458924A CA2458924A1 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy
BRPI0212625-7A BR0212625A (en) 2001-08-30 2002-08-29 casein-derived peptides and their uses in therapy
MXPA04001890A MXPA04001890A (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy.
HU0500995A HUP0500995A3 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy
EP02758768A EP1556074A4 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy
IL16054802A IL160548A0 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy
KR10-2004-7002884A KR20040078639A (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy
NO20040880A NO20040880L (en) 2001-08-30 2004-02-27 Casein-derived peptides and applications thereof in therapy.
US10/788,400 US7666996B2 (en) 2000-03-01 2004-03-01 Casein derived peptides and uses thereof
US11/982,369 US20090192081A1 (en) 2000-03-01 2007-10-31 Casein derived peptides and uses thereof
US12/844,834 US20100317601A1 (en) 2000-03-01 2010-07-28 Casein Derived Peptides And Uses Thereof
US13/603,428 US8735348B2 (en) 2000-03-01 2012-09-05 Casein derived peptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/942,121 US20020147144A1 (en) 2000-03-01 2001-08-30 Casein derived peptides and uses thereof in therapy
US09/942,121 2001-08-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000198 Continuation-In-Part WO2001064234A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/788,400 Continuation-In-Part US7666996B2 (en) 2000-03-01 2004-03-01 Casein derived peptides and uses thereof
US11/982,369 Continuation-In-Part US20090192081A1 (en) 2000-03-01 2007-10-31 Casein derived peptides and uses thereof

Publications (3)

Publication Number Publication Date
WO2003018606A2 WO2003018606A2 (en) 2003-03-06
WO2003018606A9 WO2003018606A9 (en) 2004-04-08
WO2003018606A3 true WO2003018606A3 (en) 2005-05-06

Family

ID=25477603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000720 WO2003018606A2 (en) 2000-03-01 2002-08-29 Casein derived peptides and uses thereof in therapy

Country Status (15)

Country Link
EP (1) EP1556074A4 (en)
JP (1) JP2005511499A (en)
KR (1) KR20040078639A (en)
CN (1) CN1694719A (en)
AU (1) AU2002324323A2 (en)
BR (1) BR0212625A (en)
CA (1) CA2458924A1 (en)
CZ (1) CZ2004335A3 (en)
HU (1) HUP0500995A3 (en)
IL (1) IL160548A0 (en)
MX (1) MXPA04001890A (en)
NO (1) NO20040880L (en)
PL (1) PL375113A1 (en)
WO (1) WO2003018606A2 (en)
ZA (1) ZA200401574B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping
CN101124261A (en) * 2004-03-01 2008-02-13 派普特拉医药有限公司 Casein derived peptides and therapeutic uses thereof
GB0423352D0 (en) 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2319475B1 (en) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas BIOACTIVE PEPTIDES IDENTIFIED IN ENZYMATIC HYDROLYZES OF LACTEE CASEINS AND PROCEDURE OF OBTAINING.
CN101410131B (en) * 2006-06-09 2012-09-12 森永乳业株式会社 Lipid-metabolism-improving agent
JP2011026213A (en) * 2009-07-22 2011-02-10 Snow Brand Milk Prod Co Ltd Type 1 diabetes-inhibiting peptide
EP2839291B1 (en) * 2012-04-16 2018-07-04 The Cleveland Clinic Foundation Multivalent breast cancer vaccine
CN110381964A (en) * 2017-03-03 2019-10-25 森永乳业株式会社 GLP-1 secernent and composition
CN107814835B (en) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 Bioactive polypeptide AVPITPTLNREQ, and preparation method and application thereof
CN108017709B (en) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 Bioactive polypeptide KEPMIGVNQELA, and preparation method and application thereof
CN113952446B (en) * 2021-09-03 2023-12-05 河南省医药科学研究院 Application of bioactive peptide in inhibiting bone marrow toxicity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150547A (en) * 1997-03-21 2000-11-21 Snow Brand Milk Products Co., Ltd. Iron-casein complex hydrolyzate and process for the production thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150547A (en) * 1997-03-21 2000-11-21 Snow Brand Milk Products Co., Ltd. Iron-casein complex hydrolyzate and process for the production thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARDT F. ET AL: "Occurrence of autoimmune phenomena during the development of casein-induced amyloidosis in C3H and NZB-Bl mice", ACTA PATHOL. MICROBIOL. SCAND.UA], vol. 233, 1972, pages 178 - 182, XP008045222 *
LI X.-B. ET AL: "Low incidence of autoimmune type I diabetes in BB rats fed a hydrolysed casein-based diet associated with early inhibition of non-macrophage-dependent hyperexpression of MHC class I molecules on beta cells", DIABETOLOGIA, vol. 38, no. 10, October 1995 (1995-10-01), pages 1138 - 1147, XP008045220 *
MONETINI L. ET AL: "Antibodies to bovine beta-casein in diabetes and other autoimmune diseases", HORM.METAB.RES., vol. 34, no. 8, August 2002 (2002-08-01), pages 455 - 459, XP008045221 *
WILDNER ET AL: "Autoimmune uveitis induced by molecular mimicry of peptides from rotavirus, bovine casein and retinal S-antigen", EUR. J. IMMUNOL., vol. 33, no. 9, September 2003 (2003-09-01), pages 2577 - 2587, XP002985244 *

Also Published As

Publication number Publication date
WO2003018606A9 (en) 2004-04-08
WO2003018606A2 (en) 2003-03-06
CN1694719A (en) 2005-11-09
EP1556074A4 (en) 2008-05-07
HUP0500995A2 (en) 2007-05-02
ZA200401574B (en) 2007-02-28
CA2458924A1 (en) 2003-03-06
MXPA04001890A (en) 2004-06-18
AU2002324323A2 (en) 2003-03-10
JP2005511499A (en) 2005-04-28
IL160548A0 (en) 2004-07-25
NO20040880L (en) 2004-04-20
HUP0500995A3 (en) 2008-09-29
KR20040078639A (en) 2004-09-10
EP1556074A2 (en) 2005-07-27
BR0212625A (en) 2007-06-19
CZ2004335A3 (en) 2004-07-14
PL375113A1 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
KR20030025907A (en) Casein derived peptides and uses thereof in therapy
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
AU1685499A (en) Polypeptide, their production and use
WO2003047524A3 (en) Methods and compositions for modulating the immune system and uses thereof
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
EP2301563A3 (en) HSP20 peptides
WO2000075173A3 (en) Peptide fragments of colostrinin
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2001036465A3 (en) Human zven proteins
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
WO2000027880A3 (en) Rantes-derived peptides with anti-hiv activity
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2002089828A3 (en) Interferons in the treatment of ischemia
WO2001004318A3 (en) Myxoma virus genes for immune modulation
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WO2000077177A3 (en) Isolation of a human retrovirus
MD2053B1 (en) Remedy with interferon inducing action
WO2004067024A3 (en) Hcv combination therapy
WO2002048182A3 (en) Interferon-alpha induced gene
NO964894D0 (en) Recombinant viruses, their preparation and use of gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 160548

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004/01574

Country of ref document: ZA

Ref document number: 200401574

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001890

Country of ref document: MX

Ref document number: 375113

Country of ref document: PL

Ref document number: 2003523265

Country of ref document: JP

Ref document number: 2458924

Country of ref document: CA

Ref document number: 1020047002884

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2004-335

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002758768

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 531737

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002324323

Country of ref document: AU

Ref document number: 648/CHENP/2004

Country of ref document: IN

Ref document number: 200400376

Country of ref document: EA

COP Corrected version of pamphlet

Free format text: PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/19-19/19

WWE Wipo information: entry into national phase

Ref document number: 20028216741

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2004-335

Country of ref document: CZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002758768

Country of ref document: EP